Why the study?
The study was designed to assess the prognostic significance of residual dyspnoea at discharge in patients with acute heart failure.
Does residual dyspnoea at discharge predict 1-year mortality and HF rehospitalisation in patients with acute heart failure?
Does residual dyspnoea at discharge predict 1-year mortality and HF rehospitalisation in patients with acute heart failure?
Residual dyspnoea at discharge in acute heart failure patients is a strong prognostic marker for 1-year mortality and HF rehospitalisation.
Residual dyspnoea at AHF discharge signals higher 1-year mortality risk; hypothesis-generating for targeted post-discharge trials.
OBJECTIVE: This study aimed to assess the prognostic significance of residual (discharge) dyspnoea in acute heart failure (AHF) patients. DESIGN: Single-centre, prospective observational study. SETTING: Patients hospitalised for decompensated AHF in a single cardiology centre, in Poland. PARTICIPANTS: All patients (n=202) who survived the hospitalisation with the primary diagnosis of AHF and were discharged from the hospital. PRIMARY AND SECONDARY OUTCOME MEASURES: 1-year all-cause mortality; and the composite endpoint of 1-year all-cause mortality and rehospitalisation for the HF (whichever occurred first). RESULTS: On admission, 159 (78.7%) AHF patients presented dyspnoea at rest, while residual resting dyspnoea at discharge was present in 16 patients (7.9%). There were 48 (24%) patients with moderate/severe exertional dyspnoea at discharge. In the multivariable model, the resting dyspnoea at discharge was related to a higher risk of both 1-year mortality and composite outcome, with HR (95% CI) 8.0 (3.7 to 17.3) and 5.1 (2.6 to 10.2), respectively, both p<0.0001. Analogically, moderate or severe residual dyspnoea at discharge was related to the heightened risk of study both outcomes, with HR (95% CI) 3.1 (1.8 to 5.4) and 1.8 (1.1 to 2.9), respectively, p<0.01. CONCLUSIONS: Among AHF patients the residual dyspnoea at discharge was unexpectedly common and was associated with an unfavourable outcome during 1-year follow-up.
No takes yet. Share an insight, caveat, or question.
Garus et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: